Trial Profile
A Phase I Trial of the Immunostimulant JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs JVRS 100 (Primary)
- Indications Leukaemia
- Focus Adverse reactions
- 03 Apr 2019 Status changed from active, no longer recruiting to completed.
- 26 Jan 2017 Planned End Date changed from 1 Oct 2015 to 19 Oct 2017.
- 04 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.